Clinical Trials · NCT01137682
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novartis Pharmaceuticals
- Enrollment
- 198
- Start date
- Jul 2010
- Locations
- 60 sites, 18 countries
- Primary endpoint
- Percentage of Participants With a Reduction of Mean GH Levels to < 2.5 µg/L and Normalization of Sex- and Age-adjusted IGF-1.